Durability of Response With Selpercatinib in Patients With

Authors

• Lori J Wirth
• Marcia S Brose
• Vivek Subbiah
• Francis Worden
• Ben Solomon
• Bruce Robinson
• Julien Hadoux
• Pascale Tomasini
• Daniela Weiler
• Barbara Deschler-Baier
• Daniel S W Tan
• Patricia Maeda
• Yan Lin
• Ravinder Singh
• Theresa Bayt
• Alexander Drilon
• Philippe A Cassier

Publication/Presentation Date

9-20-2024

Volume

42

Issue

27

First Page

3187

Last Page

3195

ISSN

1527-7755

Published In/Presented At

Wirth, L. J., Brose, M. S., Subbiah, V., Worden, F., Solomon, B., Robinson, B., Hadoux, J., Tomasini, P., Weiler, D., Deschler-Baier, B., Tan, D. S. W., Maeda, P., Lin, Y., Singh, R., Bayt, T., Drilon, A., & Cassier, P. A. (2024). Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 42(27), 3187–3195. https://doi.org/10.1200/JCO.23.02503

Disciplines

Medicine and Health Sciences

PubMedID

39094065

Department(s)

Hematology-Medical Oncology Division

Document Type

Article